As for α-glucosidase inhibitors (37), thiazolidinediones (38), or DPP-4 inhibitors (39), some small cohort studies might show benefits for anti-inflammation effects, but no statistical significance was found in reducing the risk of RA. This evidence concerns the gene DPP4 and rheumatoid arthritis.